Abstract Details

Title Inpatient Hospitalization Risk in Medicaid Patients with Epilepsy Before and After Perampanel Treatment

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 6-014

Objective To evaluate inpatient hospitalization risk following initiation of perampanel in Medicaid patients with epilepsy.

Background Perampanel, a non-competitive AMPA glutamate receptor antagonist, is approved for the treatment of partial-onset seizures in pediatric and adult patients with epilepsy 4 years of age and older, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.

Design/Methods Symphony Health, a nationally representative medical and pharmacy claims database, was used in this study. Medicaid patients were identified if they had filled a perampanel prescription during the period July 2014 to June 2016. The index date was the date of the first fill of the medication. Patients were selected if they were 4-11 years old with any partial-onset (focal) seizures (POS), or 12 years of age or above with any POS or any primary generalized tonic–clonic seizures (GTCS), abd had continuous observations for the one year period prior to and following this date. The outcome variables of interest were the one-year all-cause and epilepsy-related relative risk of inpatient hospitalization following perampanel initiation.

Results There were 614 Medicaid patients included in this study. Mean age was 28 years old, 56% were female. Compared to the pre-index period, the post-perampanel period was associated with a significantly lower risk of inpatient hospitalization. The one-year all-cause inpatient hospitalization risk ratio was 0.79 (p < 0.05), with 38.3% during the pre-index compared to 30.3% in the one year follow-up. Similarly, the one-year epilepsy-related inpatient hospitalization risk ratio was 0.78 (p<0.05), with 32.2% during the pre-index period, compared to 25.2% during the follow-up period.

Conclusions In Medicaid patients with epilepsy, treatment with perampanel, relative to the one-year period prior to perampanel initiation, was associated with a significant reduction in one-year all-cause and epilepsy-related inpatient hospitalization risk.

Authors/Disclosures
PRESENTER	No disclosure on file
Xuan Li (Eisai)	No disclosure on file
Manoj Malhotra, MD	Dr. Malhotra has received personal compensation for serving as an employee of Eisai.
	No disclosure on file

��ɫ��

��ɫ��